1. Scrip
  2. >>Focus On Asia
  3. >>India

Novo Nordisk’s New India Chief Steps Into Bustling Diabetes Arena

 
• By Anju Ghangurde

Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.

Shrotriya_Vikrant
Novo Nordisk India Head Vikrant Shrotriya • Source: Novo Nordisk

Top-level executive changes continue in India, with Novo Nordisk AS bringing in experienced hand Vikrant Shrotriya to helm its operations in the country.

Shrotriya, whose career spans over two decades in the healthcare industry, was more recently vice-president for Novo Nordisk’s GCC (Gulf Cooperation Council) business and corporate vice-president for Saudi Arabia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.